ArchiveApril 2013

Research: Distinguishing NMO from MS

Storoni M, Davagnanam I, Radon M, Siddiqui A, Plant GT. Distinguishing Optic Neuritis in Neuromyelitis Optica Spectrum Disease From Multiple Sclerosis: A Novel Magnetic Resonance Imaging Scoring System. J Neuroophthalmol. 2013 Apr 19. [Epub ahead of print] BACKGROUND:: The management of acute optic neuritis differs according to the underlying aetiology and techniques that may help with early...

Nature reducing their irreproducibility

#MSResearch  #EAE Time to improve your experiments This is something that is well know that many things that are published in the top journals, turn out to be not quite right.  Some people say over 50% of these papers may be crud.Why is this the case? (a) An honest error, where that was what the experimental result told you. If you aim to be first you don’t know what is right...

Research: Myelin antibodies predicting MS

van Haren K et al. Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing– remitting multiple sclerosis Mult Scler 1352458513485653, first published on April 23, 2013  Background and objective: Acute disseminated encephalomyelitis (ADEM) and relapsing–remitting multiple sclerosis (RRMS) share overlapping clinical, radiologic and laboratory...

Understanding MS genetics, Interleukin7 receptor

#MSresearch #MSblog unravelling biology behind genetics Epub: Lundström et al. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity. Proc Natl Acad Sci U S A. 2013 Apr. Human soluble interleukin-7 receptor (sIL7R)α circulates in high molar excess compared with IL-7, but its biology remains unclear. We demonstrate that sIL7Rα has moderate affinity for IL-7 but does not bind thymic...

Moving Round the Drug Monopoly Board

#MSresearch #MS Blog New drug for spasticity Canbex Therapeutics Ltd has completed a £2.1m ($3.2m) fundraising round that will enable the Company to complete the early development of its lead candidate for the treatment of spasticity in multiple sclerosis (MS). Merck Serono Ventures, the venture capital arm of Merck Serono, led the financing for this round. Canbex Therapeutics Ltd is a...

Neutriceuticals Beats Science, Where Will it All Lead?

#MSResearch #MS Blog where next science beaten

Some comments were suggesting that we are too negative about alternative and complementary medicines.
We are not against them, but we just would like to see good class I evidence.  We ask the same of pharmaceutical drugs.

Should we listen to Dr Dre and his anti-drug stance? 

What Next? 🙂

(UK) A & E = E. R. (US)

Research: Can you do a questionaire

Jongen et al. Adherence to monthly online self-assessments for short-term monitoring: a 1-year study in relapsing-remitting multiple sclerosis patients after start of disease modifying treatment. Patient Prefer Adherence. 2013 Apr 9;7:293-300.  BACKGROUND: The participation of neurologists and patients in studies on the effectiveness and safety of newly authorized drugs in...

Research: Factors influencing walking speed

Nogueira et al. Factors for lower walking speed in persons with multiple sclerosis. Mult Scler Int. 2013;2013:875648. doi: 10.1155/2013/875648.  Objective. The purpose of this study was to analyze factors related to lower walking speed in persons with multiple sclerosis (PwMS). Methods. A cross-sectional survey was conducted. The study participants were 120 consecutive PwMS, who were able to...

Factors promoting microglial activity

Xiao et al. Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation. Nat Med. 2013 Apr. doi: 10.1038/nm.3111. Microglia are crucial for the pathogenesis of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE). Here we show that the E3 ubiquitin ligase Peli1 is abundantly expressed in microglia and promotes microglial activation...

Translate

Categories

Recent Posts

Recent Comments

Archives